Prometheus Biosciences (RXDX) Stock Forecast, Price Target & Predictions


OverviewOwnershipChart

RXDX Stock Forecast


Prometheus Biosciences stock forecast is as follows: an average price target of $138.57 (represents a -30.69% downside from RXDX’s last price of $199.92) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

RXDX Price Target


The average price target for Prometheus Biosciences (RXDX) is $138.57 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $200.00 to $67.00. This represents a potential -30.69% downside from RXDX's last price of $199.92.

RXDX Analyst Ratings


Buy

According to 7 Wall Street analysts, Prometheus Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RXDX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Prometheus Biosciences Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 16, 2023Annabel SamimyStifel Nicolaus$200.00$114.0175.42%0.04%
Jan 31, 2023-Goldman Sachs$144.00$113.6626.69%-27.97%
Dec 08, 2022Jeff JonesOppenheimer$125.00$117.216.65%-37.47%
Dec 08, 2022Gregory RenzaRBC Capital$111.00$117.21-5.30%-44.48%
Dec 08, 2022Julian HarrisonBTIG$181.00$117.2154.42%-9.46%
Dec 08, 2022Tiago FauthCredit Suisse$142.00$117.2121.15%-28.97%
Dec 08, 2022Julian HarrisonBTIG$104.84$95.809.44%-47.56%
Aug 28, 2022Yasmeen RahimiPiper Sandler$67.00$49.4035.63%-66.49%
Jun 10, 2022Yasmeen RahimiPiper Sandler$53.00$26.35101.14%-73.49%
Row per page
Go to

The latest Prometheus Biosciences stock forecast, released on Apr 16, 2023 by Annabel Samimy from Stifel Nicolaus, set a price target of $200.00, which represents a 75.42% increase from the stock price at the time of the forecast ($114.01), and a 0.04% increase from RXDX last price ($199.92).

Prometheus Biosciences Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$199.92$199.92$199.92
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Prometheus Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Prometheus Biosciences's last price of $199.92. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jan 31, 2023Goldman SachsBuyBuyHold
Dec 08, 2022RBC CapitalOutperformOutperformHold
Dec 08, 2022OppenheimerOutperformOutperformHold
Dec 08, 2022Credit SuisseOutperformOutperformHold
Dec 08, 2022BTIGBuyBuyHold
Oct 04, 2022OppenheimerOutperformOutperformHold
Oct 04, 2022RBC CapitalOutperformOutperformHold
Aug 29, 2022Wells FargoOverweightOverweightHold
Aug 28, 2022Piper SandlerOverweightOverweightHold
Jun 10, 2022Piper Sandler-OverweightInitialise
Row per page
Go to

Prometheus Biosciences's last stock rating was published by Goldman Sachs on Jan 31, 2023. The company gave RXDX a "Buy" rating, the same as its previous rate.

Prometheus Biosciences Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PLRXPliant Therapeutics$14.49$39.71174.05%Buy
APLSApellis Pharmaceuticals$28.56$76.13166.56%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
ETNB89bio$9.29$22.00136.81%Buy
STOKStoke Therapeutics$13.10$30.60133.59%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
VKTXViking Therapeutics$63.14$100.5059.17%Buy
IMVTImmunovant$29.42$42.8345.58%Buy
AKROAkero Therapeutics$32.05$46.0043.53%Buy
ROIVRoivant Sciences$11.53$16.2140.59%Buy
BPMCBlueprint Medicines$91.88$109.7119.41%Buy
KRYSKrystal Biotech$170.85$191.0011.79%Buy
MDGLMadrigal Pharmaceuticals$331.32$315.75-4.70%Buy
AMLXAmylyx Pharmaceuticals$5.70$5.33-6.49%Buy
ACLXArcellx$86.44$71.57-17.20%Buy
KRTXKaruna Therapeutics$329.83$257.50-21.93%Buy
RXDXPrometheus Biosciences$199.92$138.57-30.69%Buy

RXDX Forecast FAQ


Yes, according to 7 Wall Street analysts, Prometheus Biosciences (RXDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of RXDX's total ratings.

Prometheus Biosciences (RXDX) average price target is $138.57 with a range of $67 to $200, implying a -30.69% from its last price of $199.92. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for RXDX stock, the company can go down by -30.69% (from the last price of $199.92 to the average price target of $138.57), up by 0.04% based on the highest stock price target, and down by -66.49% based on the lowest stock price target.

RXDX's average twelve months analyst stock price target of $138.57 does not support the claim that Prometheus Biosciences can reach $300 in the near future.